EGFR and neoplasm: Additionally, survival analysis was performed based on tumor fibrosis groups (<40% vs. ≥40%) and monoclonal antibody associated with chemotherapy (anti-EGFR vs. anti-VEGF) stratified by type of surgery (CR0 or CR2), considering the potential negative impact of incomplete resection (CR2) on patient survival.